16 Jul 2021 07:56
Amendment to Appendix 3H lodged 13 July 2021
16 July 2021
ASX, LSE: MXC
MGC Pharmaceuticals Ltd (ASX: MXC, 'MGC Pharma' or 'the Company') wishes to advise that the accompanying Appendix 3H, notifying of the cessation of 10,000,000 options, is being issued to amend the Appendix 3H issued on 13 July 2021.
The previously issued Appendix 3H incorrectly made reference to the cessation of 10,000,000 Fully Paid Ordinary Shares, however the notification was intended to notify the market of the cessation of 10,000,000 options which expired on 30 June 2021. As such, the Appendix 3H issued on 13 July 2021 is to be disregarded.
-Ends-
Authorised for release by the Company Secretary, David Lim, for further information please contact:
MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director +61 8 6382 3390 info@mgcpharma.com.au
| PR/IR Advisors - Media & Capital Partners Rod Hinchcliffe (IR) +61 412 277 377 Rod.Hinchcliffe@mcpartners.com.au |
UK Broker - Turner Pope Andy Thacker Andy.Thacker@TurnerPope.com Zoe Alexander +44 20 3657 0050 Zoe.Alexander@TurnerPope.com | UK PR Advisors - Tavistock Charles Vivian +44 207 920 3150 Charles.Vivian@tavistock.co.uk Tim Pearson +44 7983 118 502 Tim.Pearson@tavistock.co.uk |
About MGC Pharma
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions - epilepsy and dementia - and has further products in the development pipeline.
Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.
MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.
MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.
Follow us through our social media channels
Twitter: @MGC_Pharma
Facebook: @mgcpharmaceuticals
LinkedIn: MGC Pharmaceuticals Ltd.
Instagram: @mgc_pharma
Appendix 3H
Notification of cessation of +securities
Information and documents given to ASX become ASX's property and may be made public.
*Denotes minimum information required for first lodgement of this form.
Part 1 - Entity and announcement details
Question no | Question | Answer |
1.1 | *Name of entity We (the entity named above) provide the following information about our issued capital.[1] | MGC Pharmaceuticals Ltd |
1.2 | *Registration type and number Please supply your ABN, ARSN, ARBN, ACN or another registration type and number (if you supply another registration type, please specify both the type of registration and the registration number). | 30 116 800 269 |
1.3 | *ASX issuer code | MXC |
1.4 | \* The announcement is Select whichever is applicable. | ☐ New announcement ☒ Update/amendment to previous announcement ☐ Cancellation of previous announcement |
1.4a | *Reason for update Answer this question if your response to Q 1.4 is "Update/amendment to previous announcement". | App 3H lodged on 13 July 2021 was intended to notify the cessation of 10M options, rather than shares. |
1.4b | *Date of previous announcement to this update Answer this question if your response to Q 1.4 is "Update/amendment to previous announcement". | 13 July 2021 |
1.4c | *Reason for cancellation Answer this question if your response to Q 1.4 is "Cancellation of previous announcement". |
|
1.4d | *Date of previous announcement to this cancellation Answer this question if your response to Q 1.4 is "Cancellation". |
|
1.5 | *Date of this announcement | 16 July 2021 |
Part 2 - Details of +equity securities or quoted +debt securities that have ceased
Question No. | Question | Answer |
2.1 | *ASX +security code and description | MXCAF |
2.2 | *Number of securities that have ceased | 10,000,000 |
2.3 | *Reason for cessation Note: the conversion of a convertible security (which is notifiable to ASX under Listing Rule 3.10.3B) is not regarded as the "cessation" of the convertible security for the purposes of this rule. Likewise, the payment up of a partly paid security resulting in it becoming a fully paid security (which is notifiable to ASX under Listing Rule 3.10.3D) is not regarded as the "cessation" of the partly paid security for the purposes of this rule. | ☒ Expiry of option or other convertible security without exercise or conversion ☐ Lapse of conditional right to securities because the conditions have not been, or have become incapable of being, satisfied ☐ Cancellation pursuant to a minimum holding buy-back ☐ Cancellation pursuant to an employee share scheme buy-back ☐ Cancellation pursuant to an on-market buy-back ☐ Cancellation pursuant to an equal access scheme buy-back ☐ Cancellation pursuant to a selective buy-back ☐ Cancellation pursuant to another form of buy back ☐ Cancellation pursuant to a reduction of capital ☐ Cancellation pursuant to a scheme of arrangement or other reconstruction ☐ Cancellation by agreement between the entity and the holder ☐ Repayment or redemption of +convertible debt security without conversion ☐ Repayment or redemption of quoted +debt security ☐ Redemption of redeemable preference securities ☐ Redemption of units ☐ Cancellation of partly paid +securities upon which a call or instalment has not been paid ☐ Other If you have selected 'other' please provide additional details regarding the reason for cessation here:
|
2.4 | *Date of cessation | 30 June 2021 |
2.5 | *Is the entity paying any consideration for the cessation? Example: the payment of an amount to the holder of an option or right as consideration for the holder to agree to a cancellation of the option or right. The repayment of the principal amount of a convertible debt security or quoted debt security in accordance with its terms is not regarded as consideration paid for the cessation of that security. | No |
2.6 | *In what currency is the consideration being paid? Answer this question if your response to Q 2.5 is "Yes" | N/A |
2.6a | *Consideration amount per +security paid by the entity for the cessation Answer this question if your response to Q 2.5 is "Yes" The consideration amount per security should be provided per the currency specified in Q2.6. Note: This question is not applicable for buy-back events (i.e. Minimum Holding, Employee, On-Market, Equal Access, Selective), | N/A |
2.6b | \* Total consideration paid or payable for the securities The total consideration amount should be provided per the currency specified in Q2.6.
Note: This question is applicable to buy-back events only (i.e. minimum holding, employee share scheme, on-market, equal access scheme, selective or other), | N/A |
2.7 | Any other information the entity wishes to notify to ASX about the cessation? |
|
Repeat the above questions if you are advising the cessation of more than one security class.
Part 3 - Issued capital following changes
Following the cessation of the +securities the subject of this notification, the issued capital of the entity will comprise: | |||||
3.1 | *Quoted +equity securities and +debt securities (total number of each +class of +securities quoted on ASX)
| ||||
3.2 | *Unquoted +equity securities (total number of each +class of +equity securities issued but not quoted on ASX):
| ||||
Note: the figures provided in the tables in sections 3.1 and 3.2 above are used to calculate the total market capitalisation of the entity published by ASX from time to time. Please make sure you include in the relevant table each class of securities issued by the entity. If you have quoted CHESS Depository Interests (CDIs) issued over your securities, include them in the table in section 3.1. Restricted securities should only be included in the table in section 3.1 if you are applying to have them quoted because the escrow period for the securities has expired or is about to expire. Otherwise include them in the table in section 3.2. | |||||
Introduced 05/06/21
[1] Listing rule 3.10.3E requires an entity to notify ASX of details of the cessation of:
(a) any securities issued under an employee incentive scheme:
(i) to key management personnel or an associate, within 5 business days of their cessation;
(ii) to someone who is not key management personnel or an associate, within 10 business days of the end of the quarter in which the cessation occurred;
(b) any other equity securities not otherwise notifiable to ASX under rule 3.8A, within 5 business days of their cessation; or
(c) any quoted debt securities, within 5 business days of their cessation.
The notification must be in the form of, or accompanied by, an Appendix 3H.
Listing rule 3.8A requires an entity to notify ASX of the cessation of securities pursuant to a buy-back by giving ASX an Appendix 3H:
• in the case of a minimum holding buy-back, within 5 business days of the completion of the buyback; or
• in all other cases, within 5 business days of giving ASX the final notice for the buy-back.